Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) is a member of the NFAT family of transcription factors and serves as the master regulator of osteoclast differentiation (Takayanagi et al., 2002, PMID: 11919631). In response to RANKL signaling, NFATc1 is induced and activated through a calcium-calcineurin-dependent pathway, where calcineurin dephosphorylates NFATc1 to facilitate its nuclear translocation (Asagiri & Takayanagi, 2007, PMID: 17334360). Once in the nucleus, NFATc1 orchestrates the expression of essential osteoclast-specific genes, including TRAP, cathepsin K, and the calcitonin receptor, which are critical for bone resorption (UniProt P48744). Dysregulation of NFATc1 signaling is heavily implicated in pathological bone loss conditions such as osteoporosis and rheumatoid arthritis (Kim et al., 2014, PMID: 24814138). While direct NFATc1 inhibitors are a subject of research, current therapeutic modulation primarily occurs through calcineurin inhibitors like cyclosporine A and tacrolimus, or upstream via RANKL inhibitors like denosumab (Sitara & Aliprantis, 2010, PMID: 20157171). However, targeting NFATc1 presents challenges due to its vital role in T-cell activation and immune homeostasis, leading to potential side effects like immunosuppression (Wikipedia, NFATC1).
Inhibition of calcineurin-mediated dephosphorylation of NFATc1, which prevents its translocation to the nucleus and subsequent transcription of osteoclast-specific genes.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) (NFATc1).